Company presentation for investors

2014 Q1-Q3

ORION
Building well-being

Forward-looking statements

This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company's future activities and performance. They include statements about future strategies and anticipated benefits of these strategies.

These statements are subject to risks and uncertainties. Actual results may differ substantially from those stated in any forward-looking statement. This is due to a number of factors, including the possibility that Orion may decide not to implement these strategies and the possibility that the anticipated benefits of implemented strategies are not achieved. Orion assumes no obligation to update or revise any information included in this presentation.

Contents

ORION
Building well-being

Advances in pharmaceutical development projects

- Net sales and operating profit include significant milestone payments received from collaboration partners that were higher than in previous year
- Good growth in Specialty Products sales
- First generic competitors to Precedex entered US markets
- Recruiting of patients for ODM-201 Phase III clinical trial started (ARAMIS)
- Out of two COMT inhibitors, ODM-104 was selected for further development
- Phase I clinical trial of new FGFR+VEGFR inhibitor (ODM-203) for treatment of cancers started

Key figures



R&D expenses, EUR 78 million (+8%)

ORION Building well-being

Net sales originate mainly in Europe
Breakdown of EUR 760 million net sales in Q1-Q3/2014

Key figures by business divisions	Q1-Q3/ 2014	Change %
Net sales of Pharmaceuticals, EUR million	**721**	+4%
Proprietary Products	**285**	-0%
Specialty Products	**310**	+11%
Animal Health	**50**	-5%
Fermion	**46**	-1%
Contract manufacturing & other	**29**	-5%
Pharmaceuticals operating profit, EUR million	**219**	+7%
Net sales of Diagnostics business, EUR million	**42**	-4%
Operating profit of Diagnostics business, EUR million	**4.9**	+25%

Sales split by market area



ORION Building well-being

Best-selling pharmaceuticals Q1-Q3/2014



Products based on Orion's inventions in blue

ORION
Building well-being

Product mix is changing

Sales split by business 2011



Sales split by business Q1-Q3/2014



- Proprietary Products
- Specialty Products (generics+OTC)
- Animal Health
- Fermion
- Contract Manufacturing & other
- Orion Diagnostica

ORION Building well-being

Outlook for 2014 (unchanged)

Net sales	Net sales will be at similar level to 2013 (net sales in 2013 were EUR 1,007 million)
Operating profit	Operating profit will be at similar level to 2013 (operating profit in 2013 was EUR 268 million)
Group's capital expenditure	Group's capital expenditure will be about EUR 60 million excluding substantial corporate or product acquisitions (Group's capital expenditure in 2013 was EUR 78 million)

Orion’s strategy and financial targets

Building well-being

Profitable growth and increased shareholder value whilst keeping business risks under control



ORION Building well-being

Balancing mid-term – building long-term



ORION
Building well-being

Orion's financial objectives

Orion's financial objectives are:

- Ensuring financial stability
- Profitable growth

The objectives are achieved through:

- Increasing net sales. Achievement of this objective requires continuous investment in development of the product portfolio.
- Maintaining profitability at a good level, the aim being operating profit that exceeds 20% of net sales.
- Keeping the equity ratio at least 50%.

Operating profit



Net sales



Equity ratio and interest-bearing liabilities



ORION
Building well-being

Orion R&D – long term opportunities

Building well-being

Orion's R&D strategy

Increased productivity	R&D operational model renewed in 2009
Focused therapy areas	Focus on three core therapy areas + generics • Central nervous system diseases • Oncology and critical care • Easyhaler pulmonary drugs
Shared risks and rewards	Emphasis on collaboration and partnerships • Clinical studies are performed globally, Orion's focus on Europe • Partnerships are usually sought for clinical phase III at the latest • Partners are important in marketing authorisation cases in countries outside Europe • Orion holds the rights for further develop and market the candidate compounds
Focus on strengths	In-house R&D covers mainly late-stage research and early-stage development phases • i.e. discovery, preclinical phase and clinical phases I and II
Diversification	Constant strive to • Increase the overall number of programmes • Balance the risks of individual projects • Acquire new early research molecules • Improve the life-cycle management of own innovative treatments
M&As	Active in-licensing of drug candidates or products

ORION
Building well-being

Collaborative networks across the R&D value chain



ORION Building well-being

Key clinical pharmaceutical development projects

Project	Indication	PHASE			Registration
Bufomix Easyhaler® (budesonide-formoterol) [1)]	Asthma, COPD	I	II	III	
Easyhaler® salmeterol-fluticasone	Asthma, COPD	I	II	III	
ODM-201 (androgen receptor inhibitor) [2)]	Prostate cancer	I	II	III	
Levosimendan [3)]	Low Cardiac Output Syndrome	I	II	III	
ORM-12741 (alpha-2c adrenoceptor antagonist) [4)]	Alzheimer's disease	I	IIa		
Dexmedetomidine [5)] (intranasal)	Treatment of pain	I	IIb		
ODM-104 (more effective COMT inhibitor)	Parkinson's disease	I			
ODM-203 (targeted FGFR+VEGFR inhibitor)	Solid tumors	I			

= Phase completed

= Phase ongoing

[1)] Aim is to obtain marketing authorisation for product in at least some European countries not included in decentralised marketing authorisation application process. [2)] In collaboration with Bayer [3)] Partner: Tenax Therapeutics, Inc.
[4)] In collaboration with Janssen Pharmaceuticals [5)] Partner: Recro Pharma, Inc.

More info at: http://www.orion.fi/en/rd/orion-rd/pipeline/

Research projects 2013 (16)



Snapshot of Orion's preclinical pipeline presented at Orion Capital Markets Day on 20 November 2013.

ORION
Building well-being

ODM-201
a new generation androgen receptor (AR) inhibitor for prostate cancer

ORION
Building well-being

Partnership with Bayer – Financial terms

- Orion and Bayer will jointly develop ODM-201, with Bayer contributing a major share of the costs of future development
- Bayer will commercialize ODM-201 globally and Orion has the option to co-promote ODM-201 in Europe
- Orion is eligible to receive milestone payments from Bayer upon achievement of certain development, tech transfer and commercialization milestones
- Orion will receive substantial royalties on future sales
- Orion will be responsible for manufacturing of the product
- Orion received EUR 50 million upfront payment of which EUR 23 million was included in Q2 profit and EUR 27 million is estimated to be used for development costs of ODM-201

More info at: http://www.orion.fi/en/rd/orion-rd/pipeline/

ODM-201 has a unique profile



Enzalutamide
(MDV-3100)



ARN-509



General chemical structure
for ODM-201



- No brain entry
- No CYP inhibition or induction expected with therapeutic doses
- M0 prostate cancer market: no approved therapies

Compound	AR affinity Ki (nM)	Antagonism WT AR IC50 (nM)	Proliferation VCaP IC50 (nM)
enzalutamide	78	155	400
ARN-509	53	168	300
ODM-201	9	65	500
ORM-15341 (main metabolite)	8	25	600

*Refs. Clegg et al, Cancer Research 2012; Forster at al, Prostate 2011
** Rat autoradiography (QWBA confirms brain/plasma ratio of 14C-ODM-201 related radioactivity was 0.04-0.06, indicating negligible penetration to the brain
Source: ECC2013 poster E17-2119

More info at: http://www.orion.fi/en/rd/orion-rd/pipeline/

ORION Building well-being

ODM-201: Phase 3 study ongoing

- Phase 3 study in non-metastatic castration resistant prostate cancer (nm-CRPC) patients who are at high risk for developing metastatic disease
- Primary endpoint
  - ODM-201 over placebo in metastasis-free survival (MFS)
- Secondary endpoints
  - Overall survival, time to first symptomatic skeletal event (SSE), time to first initiation of cytotoxic chemotherapy, time to pain progression, and to characterize the safety and tolerability of ODM-201.

More info at: http://www.orion.fi/en/rd/orion-rd/pipeline/

ORM-12741, alpha-2c adrenoceptor antagonist

Building well-being

ORM-12741 – collaboration with Janssen

- Licence agreement announced on 19 December 2013 (includes ORM-12741 and other compounds)
- Orion received USD 31 million upfront payment which will mainly be used against additional Phase IIa study costs
- Orion is eligible to receive milestone payments from Janssen upon successful completion of certain development and commercialization events, as well as royalties on future sales
- Orion has exclusive commercialization rights in Europe
- Janssen has worldwide exclusive license to develop ORM-12741 and an exclusive right to commercialize it outside Europe
- Orion and Janssen will co-fund the development after an additional Phase IIa study is completed successfully by Orion

More info at: http://www.orion.fi/en/rd/orion-rd/pipeline/

ORM-12741, first Phase 2a Study in AD

- Objective
  - To evaluate safety and efficacy of ORM-12741 in treatment of cognitive and behavioral symptoms of Alzheimer's disease
- Design and Methodology
  - Randomised, double-blind, placebo-controlled, parallel-group Phase 2a study in 100 patients
  - Patients with moderately severe Alzheimer's disease (MMSE 12 - 21)
  - Behavioural and psychological symptoms present (NPI ≥ 15)
  - All on stable dose of donepezil, rivastigmine or galantamine for at least 3 months
  - 2 dose levels of ORM-12741 and placebo for 12 weeks as an add-on therapy
- Main Endpoints
  - A battery of computerized neurocognitive tests (CDR System)
    - Pre-specified primary emphasis on composite scores for Quality of Episodic Memory, Quality of Working Memory, Speed of Memory and Power of Attention
  - Neuropsychiatric inventory (NPI)
  - Safety: AEs, vital signs, safety lab, ECG

More info at: http://www.orion.fi/en/rd/orion-rd/pipeline/

ORM-12741 first Phase 2a Study — Conclusions

- Clear positive effects on memory measures on active treatment groups as compared to placebo
  - Clear and statistically significant positive treatment effect on Quality of Episodic Memory (*p=0.03)
  - Clear and statistically significant positive treatment effect on Quality of Memory (*p=0.013)
- Clear and statistically significant positive treatment effect on Neuropsychiatric Inventory (NPI) Caregiver Distress score (*p=0.034)
- Trend for positive treatment effect in Neuropsychiatric Inventory (NPI) total score for the low dose group (*p=0.12)
- ORM-12741 was generally well tolerated

*Main treatment effect (used doses: 30-60mg and 100-200 mg)

More info at: http://www.orion.fi/en/rd/orion-rd/pipeline/

ORM-12741 — Next Steps

- A new formulation study followed by
- An additional Phase 2a in AD patients focusing on
  - Confirmation of the first Phase 2a results – especially on NPI
  - Dosing
- Development options for Phase 3

Cognition

✓ Pros': Several compound shown to work, clear study designs, endpoints & regulatory path

✓ Cons': Old generic drugs on market, new competitors in pipeline, lower price expectation than for the latter

Neuropsychiatric symptoms

✓ Pros': Huge unmet need, less competition, high value

✓ Cons': Endpoints & regulatory path less clear – need clarification before Phase 3

More info at: http://www.orion.fi/en/rd/orion-rd/pipeline/

Proprietary Products and Specialty Products update

Building well-being

Product protection situation of key products

Molecule	Product	Indication	Key patents or data protection expire		
			Europe	USA	Japan
Entacapone	Stalevo®, Comtess® and Comtan®	Parkinson's disease	November 2012 October 2013 [1)]	October 2013	January 2015 [2)]
Levosimendan	Simdax®	Acute decompensated heart failure	September 2015	Not marketed	Not marketed
Dexmedetomidine	Precedex® *dexdor*®	Intensive care sedative	July 2013 September 2021 [3)]	January 2014 [4)]	June 2012

[1)] Stalevo data protection expired
[2)] Data protection of Comtan expires;
[3)] *dexdor*® data protection expires
[4)] Six months paediatric exclusivity granted for Precedex in the United States expired

ORION Building well-being

Turning points of Parkinson's franchise

Annual in-market sales, EUR million*



Orion sales, EUR million



	USA	EUROPE	JAPAN
STALEVO	First generics in April 2012	First generics in Q2/2014	
COMTESS/COMTAN	First generics in October 2012	First generics in Q4/2012	Data protection ends in January 2015

*Source: IMS Health MAT6/2014

Precedex® and *dexdor*® intensive care sedatives

European sedative market MAT6/2014

Total market value EUR 485 million (+2.4%)



- Propofol EUR 327 million (+4%)
- Midazolam EUR 74 million (-4%)
- Dexmedetomidine EUR 24 million (+34%)
- Remifentanil EUR 60 million (-8%)

Breakdown of Precedex markets



ORION Building well-being

Easyhaler® for asthma and COPD



- Easyhaler® is authorised in 30 countries and coverage expanding, excl. USA and Japan
- Rights to Easyhaler ® products repatriated in various European countries in 2012

1993 Buventol Easyhaler® (salbutamol)

1994 Beclomet Easyhaler® (beclomethasone)

2002 Buventol Easyhaler® (budesonide)

2004 Formoterol Easyhaler® (formoterol)

2014 Bufomix Easyhaler® (budesonide-formoterol)

2010→ Development of fluticasone-salmeterol

ORION Building well-being

Retail sales of inhaled respiratory drugs market in Top 5 Europe





Source: IMS Health 2013

ORION Building well-being

Launches are basis for future growth in SpP

Specialty Products launches



SpP launches in 2013

By geographic area

Eastern Europe	27
Scandinavia	37
Finland	26
Other	9



ORION Building well-being

Key financials

Building well-being

Key figures by quarter









ORION
Building well-being

Key figures for 2010—Q3/2014

Orion's key figures	2010	2011	2012	2013	Q1—Q3/2014	Q1—Q3/2013	Change %
Net sales, EUR million	849.9	917.9	980.4	1,006.9	**760.0**	734.3	+3.5%
Operating profit, EUR million	254.2	282.9	278.3	267.7	**217.2**	201.8	+7.6%
Profit before taxes, EUR million	252.6	282.0	276.6	264.0	**214.0**	199.6	+7.2%
R&D expenses, EUR million	85.5	87.5	105.8	101.9	**77.9**	72.2	+8.0%
Equity ratio, %	62.7%	64.2%	61.0%	53.6%	**55.3%**	51.5%	
Gearing, %	-12.2%	-6.9%	-1.7%	8.4%	**5.7%**	20.5%	
ROCE (before taxes), %	45.0%	49.4%	45.9%	38.5%	**38.7%**	39.4%	
Return on equity, %	40.7%	43.3%	41.0%	40.3%	**44.1%**	40.7%	
Basic earnings per share, EUR	1.31	1.49	1.47	1.46	**1.21**	1.07	+13.6%
Cash flow per share before financial items, EUR	1.26	1.10	1.23	1.02	**1.34**	0.56	+138.6%
Dividend per share, EUR	1.20	1.30	1.30	1.25			
Capital repayment per share, EUR	0.06	0.12					

ORION Building well-being

Income Statement 2010—Q3/2014

Formation of profits, EUR million	2010	2011	2012	2013	Q1—Q3/2014	Q1—Q3/2013	Change %
Net sales	849.9	917.9	980.4	1,006.9	**760.0**	734.3	+3.5%
Cost of goods sold	-283.2	-305.1	-350.8	-393.5	**-295.5**	-286.9	+3.0%
Gross profit	566.8	612.8	629.6	613.4	**464.5**	447.4	+3.8%
Other operating income and expenses	1.2	3.0	6.3	5.6	**-0.3**	3.4	-109.4%
Sales and marketing expenses	-188.9	-204.8	-206.1	-204.9	**-137.9**	-144.7	-4.7%
R&D expenses	-85.5	-87.5	-105.8	-101.9	**-77.9**	-72.2	+8.0%
Administrative expenses	-39.3	-40.6	-45.7	-44.5	**-31.2**	-32.1	-2.8%
Operating profit	254.2	282.9	278.3	267.7	**217.2**	201.8	+7.6%
Profit before taxes	252.6	282.0	276.6	264.0	**214.0**	199.6	+7.2%
Profit for the period	184.7	209.5	206.9	206.2	**170.4**	150.5	+13.2%

ORION Building well-being

Financial position

EUR million	9/14	9/13	Change%
Non-current assets total	**362.7**	352.7	+2.8%
Inventories	**185.2**	199.6	-7.2%
Trade receivables	**164.1**	157.9	+3.9%
Other receivables	**37.9**	43.7	-13.4%
Cash & cash equivalents & money market investments	**213.6**	172.8	+23.6%
Current assets total	**600.7**	574.1	+4.6%
Assets total	**963.4**	926.8	+4.0%

EUR million	9/14	9/13	Change%
Equity total	**515.6**	477.4	+8.0%
Interest-bearing non-current liabilities	**217.5**	240.8	-9.7%
Non-current liabilities total	**251.3**	284.0	-11.5%
Current liabilities total	**196.5**	165.3	+18.8%
Liabilities total	**447.8**	449.3	-0.3%
Equity and liabilities total	**963.4**	926.8	+4.0%

ORION Building well-being

Development of Net working capital





Building well-being

Dividend distribution policy

Orion's dividend distribution takes into account distributable funds and capital expenditure and other financial requirements in medium and long term to achieve the financial objectives.



ORION Building well-being

General info

Building well-being

Building well-being since 1917

Orion is an innovative, European, R&D-based, pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets

Orion in brief	2013
Net sales	EUR 1 007 million
Operating profit	EUR 268 million
R&D expenses	EUR 102 million
No. of personnel (at end of)	3,519
in Finland	2,816
in other countries	703



ORION
Building well-being

Business units

Proprietary Products

- Patented prescription drugs
- CTAs: CNS, oncology & critical care, Easyhaler pulmonary drugs
- Net sales in 2013 EUR 390 million

Fermion

- Active pharmaceutical ingredients (API's) for Orion and other companies
- Net sales in 2013 EUR 64 million (excluding supplies for own use)

Specialty Products

- Generic prescription drugs
- Self-care products
- Net sales in 2013 EUR 385 million

Contract Manufacturing & Other[1)]

- Pharmaceutical manufacturing for other companies
- Net sales in 2013 EUR 43 million

Animal Health

- Veterinary medicines and care products for pets and production animals
- Net sales in 2013 EUR 71 million

Orion Diagnostica

- Diagnostic test systems for point-of-care testing in healthcare and hygiene testing for industry
- Net sales in 2013 EUR 57 million

1) Contract manufacturing and other is included in the Pharmaceuticals business segment but is not a separate business division. It is part of the Group's Supply Chain organisation.

ORION
Building well-being

Market position strengthened in Europe

Finland
Market leader

Scandinavia
Strong domestic market position

Eastern Europe
Generics

Western and Central Europe
Strong position with proprietary products

Southern Europe
Progress with proprietary products in hospital markets



ORION
Building well-being

Orion shares are broadly held

By number of shares on 30 Sep



By number of votes on 30 Sep



Altogether 141.3 million shares and ca. 52,400 shareholders. Both share classes, A and B, are listed on NASDAQ OMX Helsinki since 1 July 2006. A share (ORNAV) has 20 votes/share and B share (ORNBV) has 1 vote/share in the AGM, but they have equal rights to assets and dividends.

Monthly updated info available at: http://orion.fi/en/Orion-group/investors/shareholders/ownership-structure/

ORION Building well-being

Orion B share performance

3 July 2006— 30 Sep 2014



ORION
Building well-being

Orion Investor Relations

Jari Karlson
CFO
jari.karlson@orion.fi
+358 10 426 2883

Tuukka Hirvonen
Communications Manager
Financial Communications & Investor Relations
tuukka.hirvonen@orion.fi
+358 10 426 2721

Heidi Ahti
Executive Assistant (Investor meeting requests)
heidi.ahti@orion.fi
+358 10 426 2169

www.orion.fi/EN/Investors

twitter.com/OrionCorpIR

ORION
Building well-being